다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Dialogues in clinical neuroscience, v.19 no.3, 2017년, pp.309 - 316
Lafaye, Genevieve (Author affiliations: AP-HP, GH Paris-Sud, Hopital Paul Brousse, Dpt Addictologie, F94800 Villejuif, France) , Karila, Laurent (INSERM U1178, F94800 Villejuif, France) , Blecha, Lisa (Author affiliations: AP-HP, GH Paris-Sud, Hopital Paul Brousse, Dpt Addictologie, F94800 Villejuif, France) , Benyamina, Amine (INSERM U1178, F94800 Villejuif, France)
AI-Helper
Cannabis (also known as marijuana) is the most frequently used illicit psychoactive substance in the world. Though it was long considered to be a “soft” drug, studies have proven the harmful psychiatric and addictive effects associated with its use. A number of elements are responsible for the incre...
Le cannabis (connu aussi sous le nom de marijuana) est la substance psychoactive la plus fréquemment utilisée dans le monde. Longtemps considérée comme une drogue « douce », des études ont prouvé les effets addictifs et psychiatriques nocifs associés à son utilisation. Un certain nombre d'éléments sont responsables de l'augmentation des complications liées à l'utilisation du cannabis, comme l'augmentation de sa puissance et une évolution du rapport entre les deux principaux composants, le Δ9-tetrahydrocannabinol (Δ9-THC) et le cannabidiol (avec une proportion plus importante de Δ9-THC). L'utilisation des cannabinoïdes synthétiques (CS) a rapidement progressé ces dernières années, principalement parmi les utilisateurs fréquents de cannabis, les CS apportant des effets psychoactifs similaires à ceux du cannabis. Cependant, leur composition et leurs propriétés pharmacologiques en font des substances dangereuses. Le cannabis a bien des propriétés thérapeutiques pour certaines indications. Ces applications thérapeutiques concernent seulement certains cannabinoïdes et leurs dérivés synthétiques. L'objectif de cet article est de résumer les développements actuels concernant le cannabis et la progression de l'utilisation des CS. Il faut entreprendre de nouvelles études pour mieux étudier le profit bénéfice-risque de l'usage médical du cannabis.
1 Pertwee R. ed. Handbook of Cannabis. Oxford University Press; 2014. Available at: http://www.oxfordscholarship.eom/view/10.1093/acprof:oso/9780199662685.001.0001/acprof-9780199662685. Published online January 2015. Accessed May 21, 2017
2 Volkow N. Compton W. Weiss S. Adverse health effects of marijuana use. N Engl J Med. 2014 371 9 879
3 Niesink R. van Laar M. Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry. 2013 4 130 24137134
4 ElSohly M. Mehmedic Z. Foster S. Gon C. Chandra S. Church J. Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol Psychiatry. 2016 79 7 613 619 26903403
5 Zamengo L. Prison G. Bettin C. Sciarrone R. Cannabis potency in the Venice area (Italy): update 2013. Drug Test Anal. 2015 7 3 255 258 25069834
6 Niesink R. Rigter S. Koeter M. Brunt T. Potency trends of 9 -tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15: potency trends of Dutch cannabis. Addiction. 2015 110 12 1941 1950 26234170
7 Di Forti M. Sallis H. Allegri F. et al Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014 40 6 1509 1517 24345517
8 Hall W. Degenhardt L. High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis. BMJ. 2015 350 h1205 25739398
9 Schubart C. Sommer I. van Gastel W. Goetgebuer R. Kahn R. Boks M. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res. 2011 130 1-3 216 221 21592732
10 Johnson L. Johnson R. Portier R. Current “legal highs.” J Emerg Med. 2013 44 6 1108 1115 23528960
11 Mills B. Yepes A. Nugent K. Synthetic cannabinoids. Am J Med Sci. 2015 350 1 59 62 26132518
12 Sarpong I. Jones F. A critical analysis of national policy relating to legal highs. Nurs Stand. 2014 28 52 35 41
13 Scocard A. Benyamina A. Coscas S. Karila L. Cannabinoïdes de synthase: une nouvelle matrice des addictions. Presse Med. 2017 46 1 11 22 28063756
14 Seely K. Patton A. Moran C. et al Forensic investigation of K2, Spice, and “bath salt” commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci int. 2013 233 1-3 416 422 24314548
15 Fattore L. Synthetic cannabinoids — further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry. 2016 79 7 539 548 26970364
16 Castellanos D. Gralnik L. Synthetic cannabinoids 2015: an update for pediatricians in clinical practice. World J Clin Pediatr. 2016 5 1 16 24 26862498
17 Fantegrossi W. Moran J. Radominska-Pandya A. Prather P. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to'-THC: mechanism underlying greater toxicity? Life Sci. 2014 97 1 45 54 24084047
18 De Luca M. Castelli M. Loi B. et al Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS135. Neuropharmacology. 2016 105 630 638 26686391
19 Cottencin O. Rolland B. Karila L. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Curr Pharm Des. 2014 20 25 4106 4111 24001292
20 Debruyne D. Le Boisselier R. Emerging drugs of abuse: current perspectives on synthetic cannabinoids. Subst Abuse Rehabil. 2015 6 113 129 26543389
21 Auwärter V. Dresen S. Weinmann W. Muller M. Putz M. Ferreiros N. “Spice” and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009 44 5 832 837 19189348
22 Gurney S. Scott K. Kacinko S. Presley B. Logan B. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev. 2014 26 1 53 78 26226970
23 Mounteney J. Griffiths P. Sedefov R. Noor A. Vicente J. Simon R. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015. Addiction. 2016 111 1 34 48 26419329
24 Archer J. Dargan P. Lee H. Hudson S. Wood D. Trend analysis of anonymised pooled urine from portable street urinals in central London identifies variation in the use of novel psychoactive substances. Clin Toxicol. 2014 52 3 160 165
25 Nelson M. Bryant S. Aks S. Emerging drugs of abuse. Emerg Med Clin North Am. 2014 32 1 1 28 24275167
26 Gunderson E. Haughey H. Ait-Daoud N. Joshi A. Hart C. A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abuse. 2014 35 2 184 189
27 Andréasson S. Allebeck P. Engström A. Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet Lond Engl. 1987 2 8574 1483 1486
28 Gage S. Hickman M. Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry. 2016 79 7 549 556 26386480
29 Murray R. Di Forti M. Cannabis and psychosis: what degree of proof do we require? Biol Psychiatry. 2016 79 7 514 515 26970362
30 Iseger T. Bossong M. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015 162 1-3 153 161 25667194
31 Englund A. Morrison P. Nottage J. et al Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol Oxf Engl. 2013 27 1 19 27
32 Di Forti M. Marconi A. Carra E. et al Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015 2 3 233 238 26359901
33 Schoeler T. Monk A. Sami M. et al Continued versus discontinued cannabis use in patients with psychosis: a systematic review and metaanalysis. Lancet Psychiatry. 2016 3 3 215 225 26777297
34 Frisher M. Crome I. Macleod J. Millson D. Croft P. Substance misuse and psychiatric illness: prospective observational study using the general practice research database. J Epidemiol Community Health. 2005 59 10 847 850 16166357
35 Aoun E. Christopher P. Ingraham J. Emerging drugs of abuse: clinical and legal considerations. R I Med J (2013). 2014 97 6 41 45 24905374
36 Tait R. Caldicott D. Mountain D. Hill S. Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila). 2016 54 1 1 13 26567470
37 Müller H. Kornhuber J. Sperling W. The behavioral profile of spice and synthetic cannabinoids in humans. Brain Res Bull. 2016 126 pt 1 37
38 Ustundag M. Ozhan Ibis E. Yucel A. Ozcan H. Synthetic cannabis-induced mania. Case Rep Psychiatry. 2015 2015 310 930
39 van Amsterdam J. Brunt T. van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol (Oxf). 2015 29 3 254 263
40 Zaurova M. Hoffman R. Vlahov D. Manini A. Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose. J Med Toxicol. 2016 12 4 335 340 27255136
41 Tyndall J. Gerona R. De Portu G. et al An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol (Phila). 2015 53 10 950 956 26555732
42 Mörkl S. Blesl C. Wurm W. Tmava A. Acute psychosis after consumption of synthetic cannabinoids. [in German]. Fortschr Neurol Psychiatr. 2016 84 3 150 154 27029042
43 Khan M. Pace L. Truong A. Gordon M. Moukaddam N. Catatonia secondary to synthetic cannabinoid use in two patients with no previous psychosis. Am J Addict. 2016 25 1 25 27 26781357
44 Spaderna M. Addy P. D'Souza D. Spicing things up: synthetic cannabinoids. Psychopharmacology (Bed). 2013 228 4 525 540
45 Chavant F. Boucher A. Le Boisselier R. Deheul S. Debruyne D. New synthetic drugs in addictovigilance. Therapie. 2015 70 2 167 189 25858573
46 Miliano C. Serpelloni G. Rimondo C. Mereu M. Marti M. De Luca M. Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Front Neurosci. 2016 10 153 27147945
47 Wells D. Ott C. The “new” marijuana. Ann Pharmacother. 2011 45 3 414 417 21325097
48 Sampson C. Bedy S. Carlisle T. Withdrawal seizures seen in the setting of synthetic cannabinoid abuse. 4m J Emerg Med. 2015 33 11 1712.e3
49 Andrabi S. Greene S. Moukaddam N. Moukkadam N. Li B. New drugs of abuse and withdrawal syndromes. Emerg Med Clin North Am. 2015 33 4 779 795 26493523
50 Nacca N. Vatti D. Sullivan R. Sud P. Su M. Marraffa J. The synthetic cannabinoid withdrawal syndrome. J Addict Med. 2013 7 4 296 298 23609214
51 Bush DM. Woodwell DA. Update: drug-related emergency department visits involving synthetic cannabinoids. Rockville, MD: US Substance Abuse and Mental Health Services Administration; 2013. The CBHSQ Report Available at: http://www.ncbi.nlm.nih.gov/books/NBK350768/. Published October 16, 2014. Accessed June 1, 2017
52 Labay L. Caruso JL. Gilson T. et al Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci int. 2016 260 31 39 26795398
53 Murray R. Quigley H. Quattrone D. Englund A. Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatr Assoc. 2016 15 3 195 204
54 Rong C. Lee Y. Carmona N. et al Cannabidiol in medical marijuana: research vistas and potential opportunities. Pharmacol Res. 2017 121 213 218 28501518
55 Watson S. Benson J. Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry. 2000 57 6 547 552 10839332
56 Schrot R. Hubbard J. Cannabinoids: medical implications. Ann Med. 2016 48 3 128 141 26912385
57 Whiting P. Wolff R. Deshpande S. et al Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015 313 24 2456 2473 26103030
58 Koppel B. Brust J. Fife T. et al Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 82 17 1556 1563 24778283
59 Gloss D. Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014 3 CD009270
60 Devinsky O. Marsh E. Friedman D. et al Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 15 3 270 278 26724101
61 O'Connell B. Gloss D. Devinsky O. Cannabinoids in treatment-resistant epilepsy: a review. Epilepsy Behav. 2017 70 pt B 341 348 28188044
62 Sloan M. Gowin J. Ramchandani V. Hurd Y. Le Foil B. The endocannabinoid system as a target for addiction treatment: trials and tribulations. Neuropharmacology. 2017 May 28. Epub ahead of print. doi:10.1016/j.neuropharm.2017.05.031. Accessed June 4, 2017
63 Hurd Y. Yoon M. Manini A. et al Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurother J Am Soc Exp Neurother. 2015 12 4 807 815
64 Prud'homme M. Cata R. Jutras-Aswad D. Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Subst Abuse. 2015 9 33 38
65 Leweke F. Piomelli D. Pahlisch F. et al Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012 2 3 e94 22832859
66 Bergamaschi M. Queiroz R. Chagas M. et al Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacol. 2011 36 6 1219 1226
67 Crippa J. Derenusson G. Ferrari T. et al Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011 25 1 121 130 20829306
68 Blessing E. Steenkamp M. Manzanares J. Marmar C. Cannabidiol as a potential treatment for anxiety disorders. Neurother J Am Soc Exp Neurother. 2015 12 4 825 836
69 Babson K. Sottile J. Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep. 2017 19 23 28349316
70 Zuardi A. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr Sao Paulo Braz 1999. 2008 30 3 271 280
71 Chagas M. Crippa J. Zuardi A. et al Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol Oxf Engl. 2013 27 3 312 316
72 Nicholson A. Turner C. Stone B. Robson P. Effect of Δ 9 -tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004 24 3 305 313 15118485
73 D'Souza D. Ranganathan M. Medical marijuana: is the cart before the horse? JAMA. 2015 313 24 2431 2432 26103026
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.